Sakar Healthcare Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sakar Healthcare has filed a quarterly compliance statement confirming that Rs. 5.76 crore raised through a preferential issue (conversion of warrants into equity shares) on December 27, 2024, has been fully utilised as per the originally disclosed objects, with no deviation or variation. Of this amount, Rs. 1.45 crore was used to prepay part of the company's borrowings from State Bank of India, Rs. 3.91 crore went towards procurement of machinery and equipment for the oncology unit (including lipid complex injections manufacturing), and Rs. 40 lakh was used for general corporate purposes. The audit committee and auditors had no adverse comments, and no monitoring agency was applicable for this issue.
This is a routine compliance filing with no negative implications. Full and timely utilisation of the raised funds in line with stated objectives signals disciplined capital deployment, which is mildly positive for shareholder confidence. The use of Rs. 1.45 crore for debt prepayment may marginally reduce interest costs going forward.